VIR vs. ADAP, SRRK, TARS, AUTL, FDMT, BCRX, IMTX, KYTX, RGNX, and RLAY
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Adaptimmune Therapeutics (ADAP), Scholar Rock (SRRK), Tarsus Pharmaceuticals (TARS), Autolus Therapeutics (AUTL), 4D Molecular Therapeutics (FDMT), BioCryst Pharmaceuticals (BCRX), Immatics (IMTX), Kyverna Therapeutics (KYTX), REGENXBIO (RGNX), and Relay Therapeutics (RLAY). These companies are all part of the "biological products, except diagnostic" industry.
Vir Biotechnology (NASDAQ:VIR) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
Vir Biotechnology presently has a consensus target price of $34.38, suggesting a potential upside of 327.55%. Adaptimmune Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 135.87%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Vir Biotechnology is more favorable than Adaptimmune Therapeutics.
Adaptimmune Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics has a net margin of -188.90% compared to Vir Biotechnology's net margin of -713.69%. Vir Biotechnology's return on equity of -34.92% beat Adaptimmune Therapeutics' return on equity.
Vir Biotechnology has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500.
In the previous week, Adaptimmune Therapeutics had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 7 mentions for Adaptimmune Therapeutics and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.50 beat Adaptimmune Therapeutics' score of 0.41 indicating that Vir Biotechnology is being referred to more favorably in the media.
65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 18.1% of Vir Biotechnology shares are owned by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Adaptimmune Therapeutics received 270 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 62.53% of users gave Adaptimmune Therapeutics an outperform vote while only 47.44% of users gave Vir Biotechnology an outperform vote.
Summary
Vir Biotechnology beats Adaptimmune Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
